Skip to main content

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

Active, not recruiting · Phase 4 · NCT04790370

Conditions: Pulmonary Embolism

At a glance

Research payments reported, 2025
$391,403
U.S. investigators named
27
Sites paid
27
Planned or actual enrollment
544

About the trial

Sponsor
Boston Scientific Corporation (with National PERT Consortium, Inc., University Medical Center Mainz)
Tested
Anticoagulation with heparin (drug), EkoSonicTM Endovascular System (device)
Dates
Started 2021-08-02; completion 2026-08
Results posted
Not yet

There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after randomization and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12 months after randomization. The study will try to find out if one of these treatments is bett…

From ClinicalTrials.gov, last updated 2026-07-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $391,403 in research payments for this study in 2025 (165 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.